Literature DB >> 29406295

Postburn Itch: A Review of the Literature.

Bernadette Nedelec1, Leo LaSalle2.   

Abstract

The problem of postburn itch has been underevaluated and undertreated in the past. However, recently published data have expanded the evidence base, which provides clinicians and their patients with new evaluation and treatment options that can help reduce and potentially eliminate the prolonged distress experienced by burn survivors faced with postburn itch. Although a gold standard evaluation method has not yet been agreed upon, there are a number of tools that have been published that clinicians can use for assessment. Epidemiological evidence has confirmed that the vast majority of both adult and pediatric burn survivors experience itch for years following injury. At discharge from the acute care hospital, 93% of burn survivors with major burn injuries report postburn itch that is still experienced by 44% of adult burn survivors 30 years postburn. Although larger surface area injuries are more likely to require a multimodal treatment approach to reduce the itch intensity as well as the episode duration and frequency, burn survivors with small surface area injuries also experience itch that needs to be addressed. A number of treatment protocols have been described that commonly call for concurrent administration of both pharmacological and nonpharmacological treatment approaches. These protocols provide clinicians with a structured, systematic approach to treatment decisions that are evidence-based. Although many questions require further investigation, the current state of the science creates an ethical imperative that all burn survivors' itch experience should be quantitatively evaluated and appropriate treatment options explored until satisfactory outcomes are obtained.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29406295

Source DB:  PubMed          Journal:  Wounds        ISSN: 1044-7946            Impact factor:   1.546


  7 in total

1.  Agreement between proxy- and self-report scores on PROMIS health-related quality of life domains in pediatric burn survivors: a National Institute on Disability, Independent Living, and Rehabilitation Research Burn Model System Study.

Authors:  Alyssa M Bamer; Kara McMullen; Steven E Wolf; Barclay T Stewart; Lewis Kazis; Camerin A Rencken; Dagmar Amtmann
Journal:  Qual Life Res       Date:  2021-02-27       Impact factor: 3.440

2.  Development of Proxy and Self-report Burn Model System Pediatric Itch Interference Scales: A National Institute on Disability, Independent Living, and Rehabilitation Research Burn Model System Study.

Authors:  Dagmar Amtmann; Alyssa M Bamer; Kara McMullen; Karen Kowalske; Jeffrey C Schneider; Nicole S Gibran
Journal:  J Burn Care Res       Date:  2021-03-04       Impact factor: 1.819

Review 3.  Antipruritic Effects of Botulinum Neurotoxins.

Authors:  Parisa Gazerani
Journal:  Toxins (Basel)       Date:  2018-03-29       Impact factor: 4.546

4.  Identification of Merkel cells associated with neurons in engineered skin substitutes after grafting to full thickness wounds.

Authors:  Jennifer M Hahn; Kelly A Combs; Christopher M Lloyd; Kevin L McFarland; Steven T Boyce; Dorothy M Supp
Journal:  PLoS One       Date:  2019-03-05       Impact factor: 3.240

5.  Conditioned place preference reveals ongoing pain in calves 3 weeks after disbudding.

Authors:  Sarah J J Adcock; Cassandra B Tucker
Journal:  Sci Rep       Date:  2020-03-02       Impact factor: 4.379

6.  Physical Management of Scar Tissue: A Systematic Review and Meta-Analysis.

Authors:  Carlina Deflorin; Erich Hohenauer; Rahel Stoop; Ulrike van Daele; Ron Clijsen; Jan Taeymans
Journal:  J Altern Complement Med       Date:  2020-06-24       Impact factor: 2.579

7.  No indications for altered EEG oscillatory activity in patients with chronic post-burn itch compared to healthy controls.

Authors:  Samantha K Millard; Klara Bokelmann; Rik Schalbroeck; Nic J A van der Wee; Nancy E E van Loey; Antoinette I M van Laarhoven
Journal:  Sci Rep       Date:  2022-03-25       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.